首页> 外国专利> Use of cannabidiol in the treatment of tuberous sclerosis complex

Use of cannabidiol in the treatment of tuberous sclerosis complex

机译:大麻素在结节性硬化症治疗中的应用

摘要

The present invention relates to the use of cannabidiol (CBD) for the treatment of tumours associated with Tuberous Sclerosis Complex (TSC). In particular the CBD was able to decrease the number and size of marker cells, pS6, in a zebrafish model of TSC. This is5 suggestive of a disease modifying effect whereby treatment with CBD could result in the reduction or prevention of the benign tumours that occur in TSC patients. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially 10 removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD. In use the CBD is given concomitantly with one or more other drugs used in the treatment of TSC. Such drugs may include rapamycin and/or everolimus.
机译:本发明涉及大麻二酚(CBD)在治疗与结节性硬化症(TSC)有关的肿瘤中的用途。特别是,在TSC的斑马鱼模型中,CBD能够减少标记细胞pS6的数量和大小。这暗示着疾病的改良作用,即用CBD治疗可以减少或预防TSC患者中发生的良性肿瘤。优选地,所使用的CBD为高度纯化的大麻提取物的形式,使得CBD以总提取物(w / w)的98%以上的含量存在,并且表征了提取物的其他成分。特别地,大麻素四氢大麻酚(THC)已被基本去除10次,至不超过0.15%(w / w)的水平,且CBD的丙基类似物大麻素(CBDV)的含量最高为1%。或者,CBD可以是合成生产的CBD。在使用中,CBD与治疗TSC的一种或多种其他药物同时使用。这样的药物可以包括雷帕霉素和/或依维莫司。

著录项

  • 公开/公告号IL271492D0

    专利类型

  • 公开/公告日2020-02-27

    原文格式PDF

  • 申请/专利权人 GW RESEARCH LIMITED;

    申请/专利号IL20190271492

  • 发明设计人

    申请日2019-12-17

  • 分类号A61K;

  • 国家 IL

  • 入库时间 2022-08-21 11:17:14

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号